Noel T. Brewer, PhD1; Neetu Abad, PhD2
doi : 10.1001/jamapsychiatry.2021.2951
JAMA Psychiatry. 2021;78(12):1301-1302
Lawrence H. Yang, PhD1,2; Bruce G. Link, PhD3,4; Ezra S. Susser, MD, DrPH5,6
doi : 10.1001/jamapsychiatry.2021.2497
JAMA Psychiatry. 2021;78(12):1303-1304
Katherine Jonas, PhD1; Anissa Abi-Dargham, MD1; Roman Kotov, PhD1
doi : 10.1001/jamapsychiatry.2021.2584
JAMA Psychiatry. 2021;78(12):1305-1306
Andrea Danese, MD, PhD1,2; Cathy Spatz Widom, PhD3,4
doi : 10.1001/jamapsychiatry.2021.2874
JAMA Psychiatry. 2021;78(12):1307-1308
Cathelijn Tjaden, MSc1,2; Cornelis L. Mulder, MD, PhD3,4; Wouter den Hollander, PhD1; Stynke Castelein, PhD5,6,7; Philippe Delespaul, PhD8,9; Rene Keet, PhD10; Jaap van Weeghel, PhD2,11; Hans Kroon, PhD1,2
doi : 10.1001/jamapsychiatry.2021.2880
JAMA Psychiatry. 2021;78(12):1309-1318
Although the importance of recovery-oriented care for people with severe mental illness (SMI) is widely acknowledged, essential elements such as personalization and involvement of significant others are not adequately implemented in practice.
Kathryn K. Ridout, MD, PhD1,2; Mubarika Alavi, MS2; Samuel J. Ridout, MD, PhD1; Maria T. Koshy, MD1; Sameer Awsare, MD1; Brooke Harris, PhD3; David R. Vinson, MD1,2; Constance M. Weisner, DrPH2; Stacy Sterling, DrPH, MSW, MPH2; Esti Iturralde, PhD2
doi : 10.1001/jamapsychiatry.2021.2457
JAMA Psychiatry. 2021;78(12):1319-1328
Population-level reports of suicide-related emergency department (ED) encounters among youth during the COVID-19 pandemic are lacking, along with youth characteristics and preexisting psychiatric service use.
Beth Han, MD, PhD, MPH1; Wilson M. Compton, MD, MPE1; Christopher M. Jones, PharmD, DrPH, MPH2; Emily B. Einstein, PhD1; Nora D. Volkow, MD1
doi : 10.1001/jamapsychiatry.2021.2588
JAMA Psychiatry. 2021;78(12):1329-1342
Mortality associated with methamphetamine use has increased markedly in the US. Understanding patterns of methamphetamine use may help inform related prevention and treatment.
Viktoriya L. Nikolova, MRes1; Megan R. B. Hall, BSc2; Lindsay J. Hall, PhD3,4,5; Anthony J. Cleare, MBBS, PhD1,6,7; James M. Stone, MBBS, PhD1,8; Allan H. Young, MD, PhD1,6,7
doi : 10.1001/jamapsychiatry.2021.2573
JAMA Psychiatry. 2021;78(12):1343-1354
Evidence of gut microbiota perturbations has accumulated for multiple psychiatric disorders, with microbiota signatures proposed as potential biomarkers. However, no attempts have been made to evaluate the specificity of these across the range of psychiatric conditions.
Jessye M. Maxwell, MSc1,2; Jonathan R. I. Coleman, PhD1,2; Gerome Breen, PhD1,2; Evangelos Vassos, MD1,2
doi : 10.1001/jamapsychiatry.2021.2983
JAMA Psychiatry. 2021;78(12):1355-1364
Urban residence has been highlighted as an environmental risk factor for schizophrenia and, to a lesser extent, several other psychiatric disorders. However, few studies have explored genetic effects on the choice of residence.
Julia M. Sealock, BSc1,2; Younga H. Lee, PhD3,4,5; Arden Moscati, PhD6; Sanan Venkatesh, BSc7,8,9,10,11,12; Georgios Voloudakis, MD, PhD7,8,9,10,11,12; Peter Straub, MS1,2; Kritika Singh, BSc1,2; Yen-Chen A. Feng, PhD3,4; Tian Ge, PhD3,4; Panos Roussos, MD, PhD7,8,9,10,11,12; Jordan W. Smoller, MD, ScD3,4,5; Guanhua Chen, PhD13; Lea K. Davis, PhD1,2,14,15,16,17
doi : 10.1001/jamapsychiatry.2021.2959
JAMA Psychiatry. 2021;78(12):1365-1374
Although depression is a common psychiatric disorder, its underlying biological basis remains poorly understood. Pairing depression polygenic scores with the results of clinical laboratory tests can reveal biological processes involved in depression etiology and in the physiological changes resulting from depression.
Henry Bode1; Beatrice Ivens1; Tom Bschor, MD2; Guido Schwarzer, PhD3; Jonathan Henssler, MD1,4; Christopher Baethge, MD1
doi : 10.1001/jamapsychiatry.2021.2506
JAMA Psychiatry. 2021;78(12):1375-1383
Hypothyroidism is considered a cause of or a strong risk factor for depression, but recent studies provide conflicting evidence regarding the existence and the extent of the association. It is also unclear whether the link is largely due to subsyndromal depression or holds true for clinical depression.
Ronald C. Kessler, PhD1; Alex Luedtke, PhD2,3
doi : 10.1001/jamapsychiatry.2021.2500
JAMA Psychiatry. 2021;78(12):1384-1390
Clinical trials have identified numerous prescriptive predictors of mental disorder treatment response, ie, predictors of which treatments are best for which patients. However, none of these prescriptive predictors is strong enough alone to guide precision treatment planning. This has prompted growing interest in developing precision treatment rules (PTRs) that combine information across multiple prescriptive predictors, but this work has been much less successful in psychiatry than some other areas of medicine. Study designs and analysis schemes used in research on PTR development in other areas of medicine are reviewed, key challenges for implementing similar studies of mental disorders are highlighted, and recent methodological advances to address these challenges are described here.
Katlyn Nemani, MD1,2; Sarah Conderino, MS3; Julia Marx, BS1; Lorna E. Thorpe, PhD, MPH3; Donald C. Goff, MD1,2
doi : 10.1001/jamapsychiatry.2021.2503
JAMA Psychiatry. 2021;78(12):1391-1393
Philip Z. Mannes, BA1; Tiffany L. Wang, MD2; Wenting Ma, BS3; Jeffrey Selzer, MD2,4,5; Carlos Blanco, MD, PhD6
doi : 10.1001/jamapsychiatry.2021.2666
JAMA Psychiatry. 2021;78(12):1393-1395
doi : 10.1001/jamapsychiatry.2021.3677
JAMA Psychiatry. 2021;78(12):1395
آیا می خواهید مدیلیب را به صفحه اصلی خود اضافه کنید؟